ACMJ
Anatolian Current Medical Journal

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2718-0115
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Total macular volume as a potential biomarker in the assessment of anti-VEGF response in patients with diabetic macular edema: real-life data analysis
Abstract
Aims: To evaluate the functional and anatomic efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with diabetic macular edema (DME) and investigate the association between central macular thickness (CMT) and total macular volume (TMV) in real-life settings. Material and
Methods: In this retrospective, observational, longitudinal study 38 eyes of 23 consecutive patients with center-involving DME were included. A loading phase of three monthly intravitreal anti-VEGF injections was initiated, followed by anti-VEGF injections if needed as per clinicians’ discretion.
Results: Mean Early Treatment Diabetic Retinopathy Study (ETDRS) letters gained was 3.2 letters at month 12. The reduction in the mean of CMT and TMV were 60 µm and 1.33 mm3 respectively at the end of 12 months. Best-corrected visual acuity (BCVA) was negatively correlated with CMT (r=-0.573, p < 0.01) and TMV (r=-0.533, p < 0.01) initially. There was a statistically significant positive correlation between the CMT and the TMV initially (r=0.765, p < 0.01) and month 12 (r=0.937, p < 0.01). Baseline TMV was found to be more predictive of treatment response at the 9th month than baseline CMT.
Conclusion: It is demonstrated that TMV may be a suitable biomarker in the assessment of treatment response of the macular region when regarded as a complete three-dimensional macular unit instead of central vertical thickness only. Although the present study contributes to a better understanding of managing DME in real-life settings, further prospective, and controlled investigations are needed.

Keywords : Aflibercept, anti-VEGF, central macular thickness, diabetic macular edema, total macular volume

Download Article


1. Lang GE. Diabetic macular edema. Ophthalmologica 2012; 227:21-9.
2. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macularedema: pathogenesis and treatment. Surv Ophthalmol 2009; 54:1-32.
3. Murakami T, Yoshimura N. Structural changes in individualretinal layers in diabetic macular edema. J Diabetes Res 2013;2013: 920713.
4. Nicoara SD. Spectral domain optical coherence tomography inthe diagnosis and monitoring of diabetic macular edema. In:OCT-Applications in Ophthalmology: IntechOpen; 2018.
5. Wu PC, Chen YJ, Chen CH, et al. Assessment of macular retinalthickness and volume in normal eyes and highly myopic eyes withthird-generation optical coherence tomography. Eye 2008; 22: 551-5.
6. Yeung L, Sun CC, Ku WC, et al. Associations between chronicglycosylated haemoglobin (HbA1c) level and macular volumein diabetes patients without macular oedema. Acta ophthalmol2010; 88: 753-8.
7. Browning DJ, Glassman AR, Aiello LP, et al. Optical coherencetomography measurements and analysis methods in opticalcoherence tomography studies of diabetic macular edema.Ophthalmology 2008; 115: 1366-71, 71 e1.
8. Dhoot DS. Incidence of new diabetic macular edema in felloweyes of patients in the VISTA and VIVID studies. InvestigOphthalmol Vis Sci 2020; 61: 278-278.
9. Bakri SJ, Malhotra M, Stoilov I. Course of diabetic retinopathyin untreated fellow eyes in RIDE and RISE: a post hoc analysis.Ophthalmic Surg Lasers Imaging Retina 2022; 53: 202-7.
10. Group ETDRSR. Fundus photographic risk factors forprogression of diabetic retinopathy: ETDRS report number 12.Ophthalmology 1991; 98: 823-33.
11. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzingsnellen visual acuity measurements. Retina. 2010; 30: 1046-50.
12. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab,or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372: 1193-203.
13. Lai TT, Chen TC, Yang CH, Yang CM, Ho TC, Hsieh YT. Treat-and-extend vs. Pro Re nata regimen of ranibizumab for diabeticmacular edema-a two-year matched comparative study. FrontMed (Lausanne) 2021; 8: 781421.
14. Group ETDRSR. Early Treatment Diabetic Retinopathy Studydesign and baseline patient characteristics: ETDRS reportnumber 7. Ophthalmology 1991; 98: 741-56.
15. Itoh Y, Petkovsek D, Kaiser PK, Singh RP, Ehlers JP. Opticalcoherence tomography features in diabetic macular edema andthe impact on anti-VEGF response. Ophthalmic Surg LasersImaging Retina 2016; 47: 908-13.
16. Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab,or ranibizumab for diabetic macular edema: two-year resultsfrom a comparative effectiveness randomized clinical trial.Ophthalmology 2016; 123 :1351-9.
17. Heier JS, Bressler NM, Avery RL, et al. Comparison of aflibercept,bevacizumab, and ranibizumab for treatment of diabeticmacular edema: extrapolation of data to clinical practice. JAMAOphthalmol 2016; 134: 95-9.
18. Csaky KG, Richman EA, Ferris FL, 3rd. Report from the NEI/FDAOphthalmic Clinical Trial Design and Endpoints Symposium.Invest Ophthalmol Vis Sci 2008; 49: 479-89.
19. Panozzo G, Parolini B, Gusson E, et al. Diabetic macular edema:an OCT-based classification. Semin Ophthalmol 2004; 19: 13-20.
20. Lukic M, Williams G, Shalchi Z, et al. Intravitreal afliberceptfor diabetic macular oedema: Moorfields&rsquo; real-world 12-monthvisual acuity and anatomical outcomes. Eur J Ophthalmol 2020;30: 557-62.
21. Korobelnik JF, Daien V, Faure C, et al. Real-world outcomesfollowing 12 months of intravitreal aflibercept monotherapy inpatients with diabetic macular edema in France: results from theAPOLLON study. Graefes Arch Clin Exp Ophthalmol 2020; 258:521-8.
22. Wykoff CC, Hariprasad SM. DRCR Protocol-T: Reconciling1- and 2-Year Data for Managing Diabetic Macular Edema.Ophthalmic Surg Lasers Imaging Retina 2016; 47: 308-12.
23. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelialgrowth factor is a critical stimulus for diabetic macular edema.Am J Ophthalmol 2006; 142: 961-9.
24. Dong N, Xu B, Chu L, Tang X. Study of 27 aqueous humorcytokines in type 2 diabetic patients with or without macularedema. PloS one 2015; 10: e0125329.
25. Hillier RJ, Ojaimi E, Wong DT, et al. Aqueous Humor CytokineLevels and Anatomic Response to Intravitreal Ranibizumab inDiabetic Macular Edema. JAMA Ophthalmol 2018; 136: 382-8.
26. Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, et al.Anatomic response to intravitreal dexamethasone implant andbaseline aqueous humor cytokine levels in diabetic macularedema. Invest Ophthalmol Vis Sci 2019; 60: 1336-43.
27. Chatziralli I, Kazantzis D, Theodossiadis G, Theodossiadis P,Sergentanis TN. Retinal layers changes in patients with diabeticmacular edema treated with intravitreal anti-VEGF agents: long-term outcomes of a spectral-domain OCT study. Ophthalmic Res2021; 64: 230-6.
28. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal Afliberceptfor Diabetic Macular Edema: 148-Week Results from the VISTAand VIVID Studies. Ophthalmology 2016; 123: 2376-85.
Article available in :
Volume 5, Issue 1, 2023
Page : 65-70
https://doi.org/10.38053/acmj.1205486
Article Information
Submitted : 15 Kas 2022
Accepted : 12 Oca 2023
Corresponding Author :

Eren Ekici: Ankara Etlik City Hospital, Department of Ophthalmology, Ankara, Turkey

[email protected]
Citation : Ekici E, Altıntaş A. Total macular volume as a potential biomarker in the assessment of anti-VEGF response in patients with diabetic macular edema: real-life data analysis. Anatolian Curr Med J 2023; 5(1); 65-70.

Read: 96
Cited: 0
Download : 94
_Footer